Evidence map›Paper›PMID 34208868›Full record

ArticleJournal of clinical medicine2021

Transferrin Isoforms, Old but New Biomarkers in Hereditary Fructose Intolerance.

Ainara Cano, Carlos Alcalde, Amaya Belanger-Quintana, Elvira Cañedo-Villarroya, Leticia Ceberio, Silvia Chumillas-Calzada, Patricia Correcher, María Luz Couce, Dolores García-Arenas, Igor Gómez and 12 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Hereditary fructose intolerance: A comprehensive review.World journal of clinical pediatrics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 1 country.

Ainara CanoBiocruces Bizkaia Health Research Institute, 48093 Barakaldo, Spain.ORCID 0000-0001-6019-8926
Carlos AlcaldePaediatrics Unit, Río Hortega University Hospital, 47012 Valladolid, Spain.
Amaya Belanger-QuintanaMetabolic Diseases Unit, Department of Paediatrics, Ramon y Cajal Hospital, 28034 Madrid, Spain.
Elvira Cañedo-VillarroyaDepartment of Metabolism Diseases and Nutrition, Niño Jesús University Children's Hospital, 28009 Madrid, Spain.ORCID 0000-0002-6610-5644
Leticia CeberioInternal Medicine Service, Cruces University Hospital, 48903 Barakaldo, Spain.
Silvia Chumillas-Calzada12 de Octubre University Hospital, CIBERER, 28041 Madrid, Spain.
Patricia CorrecherNutrition and Metabolic diseases Unit, La Fe University Hospital, 46026 Valencia, Spain.
María Luz CouceUnit of Diagnosis and Treatment of Congenital Metabolic Diseases, Department of Paediatrics, IDIS-Health Research Institute of Santiago de Compostela, CIBERER, MetabERN, Santiago de Compostela University Clinical Hospital, 15704 Santiago de Compostela, Spain.ORCID 0000-0003-4861-9905
Dolores García-ArenasDepartment of Paediatric Gastroenterology, Hepatology and Nutrition, Sant Joan de Déu Hospital, 08950 Barcelona, Spain.
Igor GómezAraba University Hospital, 01009 Gasteiz, Spain.
Tomás HernándezPaediatric Service, Albacete University Hospital, 02006 Castilla-La Mancha, Spain.
Elsa Izquierdo-GarcíaPharmacy Department, Infanta Leonor University Hospital, 28031 Madrid, Spain.ORCID 0000-0002-2173-1027
Dámaris Martínez ChicanoDepartment of Paediatric Gastroenterology, Hepatology and Nutrition, Sant Joan de Déu Hospital, 08950 Barcelona, Spain.
Montserrat Morales12 de Octubre University Hospital, CIBERER, 28041 Madrid, Spain.
Consuelo Pedrón-GinerGastroenterology and Nutrition Section, Niño Jesús University Children's Hospital, 28009 Madrid, Spain.
Estrella Petrina JáureguiClinical Nutrition Section, Navarra University Hospital, 31008 Pamplona, Spain.
Luis Peña-QuintanaPediatric Gastroenterology, Hepatology and Nutrition Unit, Mother and Child Insular University Hospital Complex, Asociación Canaria para la Investigación Pediátrica (ACIP), CIBEROBN, University Institute for Research in Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain.ORCID 0000-0001-6052-5894
Paula Sánchez-PintosUnit of Diagnosis and Treatment of Congenital Metabolic Diseases, Department of Paediatrics, IDIS-Health Research Institute of Santiago de Compostela, CIBERER, MetabERN, Santiago de Compostela University Clinical Hospital, 15704 Santiago de Compostela, Spain.ORCID 0000-0003-4992-1305
Juliana Serrano-NietoPaediatric Service, Málaga Regional University Hospital (HRU), 29010 Málaga, Spain.
María Unceta SuarezBiochemistry Laboratory, Metabolism Area, Cruces University Hospital, 48903 Barakaldo, Spain.
Isidro Vitoria MiñanaNutrition and Metabolic diseases Unit, La Fe University Hospital, 46026 Valencia, Spain.ORCID 0000-0003-4450-1213
Javier de Las HerasBiocruces Bizkaia Health Research Institute, 48093 Barakaldo, Spain.ORCID 0000-0001-5663-537X
Hospital de Cruces · ESHospital Infantil Universitario Niño Jesús · ESHospital Sant Joan de Déu Barcelona · ESHospital Universitari i Politècnic La Fe · ESInstituto de Investigación Sanitaria de Santiago · ESResearch Institute Hospital 12 de Octubre · ESBioCruces Health research Institute · ESHospital Regional Universitario de Málaga · ESHospital Universitario Araba · ESHospital Universitario Infanta Leonor · ESHospital Universitario Río Hortega · ESInstituto Cajal · ESUniversidad de Las Palmas de Gran Canaria · ESUniversidad de Navarra · ESUniversity of the Basque Country · ES

Funding

Eusko Jaurlaritza Exp. No. 2018111095Federación Española de Enfermedades Raras FI18053
6 · The paper itself

Abstract

Hereditary Fructose Intolerance (HFI) is an autosomal recessive inborn error of metabolism characterised by the deficiency of the hepatic enzyme aldolase B. Its treatment consists in adopting a fructose-, sucrose-, and sorbitol (FSS)-restrictive diet for life. Untreated HFI patients present an abnormal transferrin (Tf) glycosylation pattern due to the inhibition of mannose-6-phosphate isomerase by fructose-1-phosphate. Hence, elevated serum carbohydrate-deficient Tf (CDT) may allow the prompt detection of HFI. The CDT values improve when an FSS-restrictive diet is followed; however, previous data on CDT and fructose intake correlation are inconsistent. Therefore, we examined the complete serum sialoTf profile and correlated it with FSS dietary intake and with hepatic parameters in a cohort of paediatric and adult fructosemic patients. To do so, the profiles of serum sialoTf from genetically diagnosed HFI patients on an FSS-restricted diet (

Indexed as

aldolase Bbiomarkerdietfructosehereditary fructose intolerancesialotransferrin profilesorbitolsucrose

Identifiers

PMID34208868
PMCPMC8267838
OpenAlexW3173199477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.